Dr. Berenson Discusses the Carfilzomib Toxicity Profile

James R. Berenson, MD
Published: Friday, Nov 18, 2011

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research (IMBCR), Chief Executive Officer, Oncotherapeutics, compares the neurotoxicity profile for the investigatory multiple myeloma agent carfilzomib to bortezomib (Velcade), an already approved treatment for multiple myeloma.

Berenson describes carfilzomib as being less peripherally and centrally neurotoxic than bortezomib. Many of these drugs, such as thalidomide, often affect mental function and some patients have complained of an inability to multitask.

Carfilzomib exhibited less neuropathic side effects in encouraging results from preclinical trials. In the clinic all grades of neuropathy were shown to be less than single-agent bortezomib. It may be possible, however, to adjust the neuropathic side effects entailed by bortezomib by changing the dosing schedule and administration route.

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research (IMBCR), Chief Executive Officer, Oncotherapeutics, compares the neurotoxicity profile for the investigatory multiple myeloma agent carfilzomib to bortezomib (Velcade), an already approved treatment for multiple myeloma.

Berenson describes carfilzomib as being less peripherally and centrally neurotoxic than bortezomib. Many of these drugs, such as thalidomide, often affect mental function and some patients have complained of an inability to multitask.

Carfilzomib exhibited less neuropathic side effects in encouraging results from preclinical trials. In the clinic all grades of neuropathy were shown to be less than single-agent bortezomib. It may be possible, however, to adjust the neuropathic side effects entailed by bortezomib by changing the dosing schedule and administration route.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x